39 results about "Immune recognition" patented technology

The invention discloses a universal HLA antigen presentation prediction method based on a protein language model and a multi-modal neural network, which comprises the following steps: firstly, extracting verified HLA binding peptide fragment sequences from an immune epitope database, generating equivalent non-epitope peptide fragment sequences in combination with a protein database, and constructing an HLA-I class and HLA-II class balanced data set; then, extracting sequence embedding characteristics and contact graph structure information of the peptide fragment sequence by utilizing a protein language model; the method comprises the following steps: processing a protein map constructed by a contact map through a map neural network to obtain global structure features, and meanwhile, carrying out regional convolution and residual convolution processing on sequence embedding by adopting a one-dimensional convolutional neural network (1DCNN) to extract local context sequence features; the method effectively fuses sequence semantics and space structure information, improves the accuracy and generalization ability of HLA antigen presentation prediction, and is suitable for immune recognition modeling tasks under various HLA subtypes.

The invention discloses an industrial control network risk monitoring method based on immune recognition, and relates to the technical field of network security risk monitoring, and the method comprises the steps: obtaining multi-source heterogeneous industrial control protocol flow data and a known data set which are collected in real time; preprocessing the data to obtain a standardized antigen vector; according to the standardized antigen vector, carrying out mixed training on a preset depth auto-encoder and a graph neural network model based on an immune algorithm to obtain a trained depth auto-encoder-graph neural network model and an initial detector population; inputting the standardized antigen vector into a lightweight model to obtain a compressed antigen vector; and detecting the compressed antigen vector based on the initial detector population to obtain an antigen vector for triggering an alarm. According to the method, the definition and expandability of original protocol semantics are improved, continuous coverage of unknown attacks is ensured, and the deployment and updating process of the model is optimized.

Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. The derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and uses thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.

The application discloses a kind of rice mycotic acid hapten and antigen preparation application, it is related to antigen preparation technical field, introduce sulfydryl in the 2 of rice mycotic acid, and obtain rice mycotic acid antigen by coupling with protein through connecting arm, rice mycotic acid hapten and antigen preparation application include the following specific flow: S1, the synthesis of rice mycotic acid hapten;S2, the preparation of rice mycotic acid immunogen;S3, the preparation of rice mycotic acid coating original;S4, the preparation of rice mycotic acid monoclonal antibody;S5, the preparation of rice mycotic acid immunofluorescence detection card;S6, rice mycotic acid detection in food;S7, detection limit experiment;S8, false positive rate, false negative rate experiment.The rice mycotic acid hapten retains the structural characteristics of rice mycotic acid, better exposes rice mycotic acid structural characteristics, improves the immunity and immune recognition ability of antigen, lays foundation for preparing specific, high sensitivity antibody, and improves its rapid detection ability.

The invention discloses a doxorubicin polymer prodrug loading method, which adopts linear or T-shaped structure polyethylene glycol as a polymer carrier, when the polymer carrier is the linear structure polyethylene glycol, the volume ratio of the polymer carrier to doxorubicin is (1-5): 1, and the volume concentration of the doxorubicin is 2-10%; when the polymer carrier is polyethylene glycol with a T-shaped structure, the volume ratio of the polymer carrier to the adriamycin is 1: 1, and the volume concentration of the adriamycin is 2-10%. Compared with the prior art, the doxorubicin can be efficiently wrapped, the targeting and controllability of drug release are improved, the immune recognition and rejection of an organism to a drug carrier are reduced, and the safety and tolerance of the drug are improved.

Provided herein are CD70-targeted chimeric antigen receptors (CARs), genetically engineered cells such as T cells containing the same, and related methods and uses of the genetically engineered cells in allogeneic cell therapy. Also provided are T cells that are genetically engineered with a CAR, such as a CD70-targeted CAR, and are further genetically engineered by one or more strategies to reduce host immune recognition of the engineered T cells, such as by heterologous expression of one or more additional transgenes and by genetic disruption to reduce or eliminate expression or one or more endogenous protein. Also provided are methods of making and using the engineered T cells for cell therapy, including in connection with cancer immunotherapy comprising adoptive transfer of the engineered T cells.

The invention discloses a flow type single molecule detection probe and method based on rolling circle amplification and application in the technical field of biomolecule detection. The flow type single molecule detection probe comprises a plurality of groups of magnetic bead detection probes and antibody binding probes which are used in pairs, each magnetic bead detection probe comprises a superparamagnetic microsphere, and the surface of the superparamagnetic microsphere is covalently connected with a plurality of fixed antibody probes; each fixed antibody probe comprises a first antibody and a first fixed DNA chain; each antibody binding probe comprises a second antibody and a second fixed DNA chain; aiming at the same target antigen, the first antibody and the second antibody in the same group can be specifically combined with different epitopes of the target antigen to form a sandwich immune complex. According to the invention, the hairpin structure DNA probe is combined with the adjacent ligation and rolling circle amplification technology to form dual specific screening of immune recognition and DNA ligation, so that the signal-to-noise ratio and sensitivity of detection are remarkably improved, and the design complexity, development cost and cross reaction risk of a multi-target detection system are greatly reduced.

The invention discloses a non-physical isolation digital ELISA detection method based on a fluorescent microsphere probe, a kit and application, and belongs to the technical field of biomedical detection. The method depends on a high-brightness fluorescent microsphere probe, realizes single-molecule immune recognition visualization and fluorescent particle digital counting under the condition of no physical isolation structure, simplifies system configuration based on an open type flat immune chip, improves the performance of a detection platform, overcomes the limitation of physical isolation type digital ELISA, is highly compatible with common equipment, and is suitable for large-scale popularization and application. The adaptation and popularization cost is reduced, and the portability and adaptability are good. High-brightness silicon-based fluorescent microspheres doped with fluorescent nanoparticles are adopted, so that high-sensitivity detection is realized; and establishing a database by using a standard product to realize absolute quantitative analysis. The kit takes a fluorescent silicon microsphere probe as a carrier, target protein can be accurately captured, non-specific adsorption is reduced, the function division of an open type flat chip is clear, and the operation is simple and convenient; the traditional detection sensitivity limitation can be broken through, the low-abundance protein is accurately quantified, the background noise interference is reduced, the detection specificity and accuracy are improved, and the early diagnosis of diseases is assisted.

This invention relates to compounds, compositions and methods for treating, reversing or preventing cancer through the modulation of immune responses via Killer-specific Secretory Protein 37 (Ksp37). By enhancing immune recognition, Ksp37 downregulates the checkpoint proteins CD47 and CD24 on abnormal cells, allowing the immune system to effectively identify and eliminate cancerous cells. Additionally, Ksp37 influences cytokine signalling by increasing IL-12 and decreasing IL-2 levels, which supports the activation of natural killer (NK) cells while mitigating chronic inflammation, fostering an immune environment conducive to clearing abnormal cells.

Provided herein are genetically engineered T cells containing a chimeric antigen receptor (CARs), and related methods and uses thereof in allogeneic cell therapy. In some embodiments, the T cells are genetically engineered with a CAR and are further genetically engineered by one or more strategies to reduce host immune recognition of the engineered T cells, such as by heterologous expression of one or more additional transgenes and by genetic disruption to reduce or eliminate expression or one or more endogenous protein. Also provided are cell compositions containing the engineered T cells, and related methods, kits and systems for producing the engineered T cells. Also provided are methods of making and using the engineered T cells for cell therapy, including in connection with cancer immunotherapy comprising adoptive transfer of the engineered T cells.

The invention discloses a high-affinity anti-human and monkey PCSK9 antibody and application thereof, and belongs to the field of biological medicine. The anti-human PCSK9 antibody comprises a heavy chain variable region of which the sequence is SEQ ID NO.1 and a light chain variable region of which the sequence is SEQ ID NO.2, or a heavy chain variable region of which the sequence is SEQ ID NO.3 and a light chain variable region of which the sequence is SEQ ID NO.4. The six anti-human PCSK9 antibodies are obtained by immunizing mice with human PCSK9 protein and combining with a hybridoma cell line and screening, and can be combined with human PCSK9 with high affinity and high selectivity, so that the combination of the human PCSK9 and LDLR (Low Density Lipoprotein Receptor) on a cytoplasmic membrane is blocked, and the degradation of the LDLR is reduced. PCSK9 is highly expressed in tumors, tumor immune recognition and CD8 + T cell anti-tumor activity are inhibited, and the PCSK9 participates in tumor immune escape. The anti-human PCSK9 antibody provided by the invention can provide candidate antibody molecules for tumor immunotherapy.

A multi-functional near-infrared fluorescent polymer dot (Pdot)-siRNA nanoplatform is disclosed herein. The disclosed technology addresses challenges in siRNA delivery, including poor stability, degradation, and immune recognition, by utilizing positively charged Pdots synthesized from polymers, and electrostatic binding with negatively charged siRNA. The Pdots exhibit dual fluorescence emission at 588 nm and 775 nm, enabling real-time visualization of cellular uptake and siRNA delivery. The nanoplatform demonstrates efficient inhibition of target gene expression, and protein levels in cells. The Pdots provide minimal toxicity and persist in cells for extended periods, offering a robust tool for therapeutic applications, bioimaging, and molecular labeling. This approach combines siRNA delivery with simultaneous imaging, presenting a versatile method for targeted gene regulation and research applications.

Although immune checkpoint blocking (ICB) therapy has significantly improved the prognosis of metastatic melanoma, most patients have not gained long-term benefits. Previous studies show that a part of causes of treatment failure are insufficient immune recognition of tumor antigen (TA). The cancer vaccine can potentially provide a complementary approach to enhance anti-tumor immunity and act synergistically with ICI. Described herein are novel tumor antigens common to most melanoma cells. Several tumor antigens described herein are derived from aberrantly expressed, non-mutated genomic sequences, such as intragene and intergene sequences, which are not expressed in normal tissue. Nucleic acids, compositions, cells and vaccines derived from these tumor antigens are described. The use of the tumor antigens, nucleic acids, compositions, cells and vaccines for the treatment of melanoma is also described.

According to the echinococcus granulosus vaccine based on the self-assembly peptide, a peptide fragment, rich in dominant epitopes, in EgG1Y162-2 is connected to a Q11 amino terminal through '-SGSG-', due to the self-assembly effect of the Q11 peptide, the peptide fragment rich in dominant epitopes is repeatedly expressed on the surface of nanofibers, and therefore EgG1Y162 dominant multi-epitope self-assembly nano-polypeptide is formed; the EgG1Y162 dominant multi-epitope self-assembled nano polypeptide is adopted in the vaccine, so that the immune recognition and response of a body are effectively enhanced.

Provided herein are genetically engineered T cells containing a chimeric antigen receptor (CARs), and related methods and uses thereof in allogeneic cell therapy. In some embodiments, the T cells are genetically engineered with a CAR and are further genetically engineered by one or more strategies to reduce host immune recognition of the engineered T cells, such as by heterologous expression of one or more additional transgenes and by genetic disruption to reduce or eliminate expression or one or more endogenous protein. Also provided are cell compositions containing the engineered T cells, and related methods, kits and systems for producing the engineered T cells. Also provided are methods of making and using the engineered T cells for cell therapy, including in connection with cancer immunotherapy comprising adoptive transfer of the engineered T cells.

The present invention discloses extracellular vesicles or EVs designed for targeted delivery of bio- therapeutics and gene editing tools, to the cells and tissues. These engineered EVs comprise novel synthetic signal sequences, which facilitate efficient cargo loading. The EVs further comprise specific targeting moieties to locate and attach to target or recipient cells, components to evade immune system detection and potential rejection, inhibit phagocytosis by immune cells, minimize immunogenicity and reduce the likelihood of immune recognition as foreign entities.

The invention discloses an intelligent artificial bionic DC cell nanoparticle nDC-M and a preparation method, application and a detection method thereof. The nano-particle is of a core-shell structure, the inner core is a hypoxia response type nano-micelle of a sound-sensitive agent SP8 and IL-2 for activating T cells to be mature, the outer layer is coated with a mature DC cell membrane, and the nano-particle has the immune recognition characteristic and the treatment function. In a tumor hypoxic microenvironment, the micelle specifically releases SP8 and IL-2; sP8 generates ROS through ultrasonic excitation, tumor cell immunogenicity death is induced, and antigens are released; iL-2 activates proliferation and functions of tumor infiltration lymphocytes; the outer DC cell membrane and the antigen capture functional group enhance the collection and activation of immune cells through surface antigen presentation, and amplify the anti-tumor immune response. By combining sonodynamic therapy and immunoregulation, tumor growth is inhibited, metastatic load is reduced, good biocompatibility and safety are achieved, and a novel bionic delivery system is provided for metastatic tumor immune combined therapy.

The present application relates to a kind of encoding aspergillus fumigatus chimeric antigen circular RNA and its application, belong to biomedical and vaccine technology field.The present application first applies circular RNA technology to anti-aspergillus fumigatus infection, provides new strategy for fungal vaccine development.Select the non-transmembrane region of aspergillus fumigatus cell membrane protein FtrA to construct antigen, avoid the transmembrane region expression problem and immune recognition uncertainty;Fusion IgK signal peptide and Fc domain, significantly improve antigen secretion efficiency, stability and immune presentation effect.LNP delivery system mature, efficient, can effectively deliver vaccine to host cell and express antigen, the LNP@CircRNA provided by the present application, especially the LNP@CircRNA FtrA2 , can induce high level of IgG antibody and T cell immune response in mouse in vivo without using adjuvant, realize the dual activation of humoral immunity and cellular immunity.

The invention provides a design method for improving the population coverage rate of a multi-epitope vaccine, which comprises the following steps: carrying out epitope prediction on B cells and T cells according to candidate proteins to obtain B cell epitopes and T cell epitopes; setting a sliding window for the candidate antigen protein; judging whether the needed epitope exists in the sliding window or not; if the needed epitope exists, shortening the length of the window by one amino acid, and judging whether the specifically bound MHC-I / II allele is reduced or not; if the MHC-1 / II allele is reduced, the window shortening operation is revoked, and overlapping epitopes which are specifically combined with the maximum MHC-1 / II allele are reserved, so that candidate overlapping epitopes are obtained. According to the invention, a three-type epitope maximization strategy based on a sliding window is adopted, and population coverage rate maximization and dual immune recognition are realized in a vaccine construct with a compact structure by recognizing the number of specific binding MHC-I / II alleles and the number of partially overlapped B cell epitope amino acids.

The present invention relates to a method for calculating binding free energy of an MHC-peptide and a method for screening an MHC-peptide, in which an initial structure of any unknown candidate MHC-peptide is obtained by adjusting amino acids in known MHC-peptide data using a template construction technique. The construction of an accurate MHC-peptide template is the premise of accurately calculating the affinity, and the application adopts a template selection method based on anchor point amino acid and aims to select the template by combining highly conservative structural characteristics of a slot (such as a hydrophobic pocket and an alpha helix-beta-sheet combination). The method is different from a traditional template matching method based on sequence similarity, particularly emphasizes selective binding of head and tail amino acids (anchor point amino acids) of the polypeptide and two ends of an MHC binding slot, and is beneficial to improving the accuracy and reliability of modeling. Compared with the prior art, the application shows powerful performance in the aspect of polypeptide affinity prediction, and lays a foundation for further understanding an immune recognition mechanism and enhancing research on MHC-peptide interaction.

The invention discloses a nano-enzyme mediated SERS (Surface Enhanced Raman Scattering) immunodetection method without a Raman nano-label, which can be used for detecting low-concentration biomarkers and improving the sensitivity of SERS detection. The method comprises the following steps: step 1, combining a metal nano-enzyme with a recognition antibody to obtain a nano-enzyme modified by the recognition antibody; combining the capture antibody with an SERS immune substrate to obtain a capture antibody modified SERS immune substrate; step 2, dropwise adding an antigen to be detected on the SERS immune substrate modified by the capture antibody, and incubating; after immune recognition, washing the SERS immune substrate with a PBS buffer solution; nano-enzyme modified by the recognition antibody is dropwise added to the SERS immune substrate and incubated, and the nano-enzyme modified by the recognition antibody and the SERS immune substrate modified by the capture antibody are combined through an antigen; 3, a color developing solution is dropwise added into the SERS immune substrate, and after incubation, quantitative detection is conducted on antigens through a Raman spectrometer.

The invention relates to the technical field of medicines, in particular to a linear nucleic acid structure with a cGAS-STING excitation function and application of the linear nucleic acid structure. According to the invention, a stable DNA nanostructure is designed and synthesized, and is modified by the aptamer, so that the targeting and stability of nucleic acid are improved, and the requirement of activating a cGAS-STING pathway is met. The composite material has good biocompatibility, and can effectively activate an immune system and enhance immune recognition and killing effects on tumor cells. In vitro and mouse tumor models, the prepared nano-carrier can activate the STING pathway, can also significantly improve the tumor immunotherapy effect, and has good preclinical application prospects in the aspects of prolonging the tumor lifetime and slowing down tumor progression. The invention provides a new strategy and technical support for tumor immunotherapy, can be used as a carrier to effectively transfer drugs, and has wide application value.

The present disclosure provides immunogenic compositions and methods for vaccination with a CelTOS immunogen. The immunogenic composition comprises Babesia, Theileria or Cytauxzoon CelTOS. The immunogenic composition may also comprise CelTOS with structural changes that affect immune recognition.

The invention discloses a tissue engineering heart valve for promoting endothelialization and a preparation method and application thereof, and belongs to the technical field of biomedical materials. Comprising the following steps: S1, preparing red cell membrane vesicles RBCM-Ab; s2, preparation of the 2dDR-PLGA-NPs (2, 2 '-(2, 2'-(2, 2 S3, preparation of RBCM-Ab / 2dDR (at) PLGA (poly (lactic-co-glycolic acid)) nanoparticles; s4, preparing the decellularized heart valve DHV; s5, preparation of the tissue engineering heart valve NP-CHS-DHV (tissue engineering heart valve); by means of the method, the tissue engineering heart valve NP-CHS-DHV capable of promoting endothelialization can be obtained. According to the invention, the blood compatibility is improved, the platelet adhesion and immune recognition are reduced, and the acceleration of endothelialization is also realized. The invention provides an innovative strategy, and the endothelialization efficiency and the clinical application prospect of the tissue engineering heart valve can be remarkably improved.

The application provides a gold-silver alloy nanoflower SERS substrate and a preparation method and application thereof. 3+ and Ag + The preparation method is as follows: an aluminum foil paper substrate is placed in a growth solution containing Au 3+ and Ag + , a gold-silver alloy nanoflower array pattern layer with a multi-level branch structure is formed on the surface of the aluminum foil paper substrate by a displacement reaction of aluminum and noble metal ions in situ. The gold-silver alloy nanoflower array pattern layer has rich nanotips and a three-dimensional rough structure, can form a large number of electromagnetic 'hot spots', and can significantly enhance the Raman signal intensity. Relying on the excellent SERS enhancement performance, the gold-silver alloy nanoflower SERS substrate is applied to an immune recognition mediated sandwich detection mode, and high-sensitivity and accurate detection of a hidden blood marker in a fecal sample is realized. The preparation process is simple, the cost is low, and complex equipment is not needed; the obtained SERS substrate has strong stability and excellent repeatability, and can meet the needs of early screening and on-site rapid detection of digestive diseases.

The invention belongs to the technical field of microorganisms and genetic engineering. The invention provides a listeria monocytogenes strain as well as a preparation method and application thereof, the flagellum formation ability of the strain is enhanced, the environmental stress resistance is enhanced, and the immune recognition of host cells on listeria monocytogenes can be enhanced; the strain is subjected to delta yxeA gene deletion mutation; the bacterial strain is named as Listeria monocytogenes Lm-delta lmo2568, the preservation number of the bacterial strain is CGMCC (China General Microbiological Culture Collection Center) No.36001, and the bacterial strain is preserved in the China General Microbiological Culture Collection Center on September 22, 2025. The invention finds that the deletion of Listeria monocytogenes YxeA promotes the formation and expression of flagellum, and the obtained strain can enhance the immune recognition of host cells on Listeria monocytogenes, and can be used for preparing related preparations.

The present invention discloses an endothelialization-promoting tissue-engineered heart valve and its preparation method and application, belonging to the technical field of biomedical materials. It includes the following steps: S1, preparation of red blood cell membrane vesicles RBCM-Ab; S2, preparation of 2dDR-PLGA-NPs nanoparticles; S3, preparation of RBCM-Ab / 2dDR@PLGA nanoparticles; S4, preparation of decellularized heart valve DHV; S5, preparation of tissue-engineered heart valve NP-CHS-DHV; through this method, the endothelialization-promoting tissue-engineered heart valve NP-CHS-DHV can be obtained. The present invention not only improves blood compatibility, reduces platelet adhesion and immune recognition, but also realizes the acceleration of endothelialization. The present invention provides an innovative strategy, which can significantly improve the endothelialization efficiency and clinical application prospect of tissue-engineered heart valves.

This invention relates to a method for predicting T lymphocyte antigen binding based on residual graph attention, belonging to the field of bioinformatics. First, a heterogeneous graph structure and node features of T lymphocytes and antigens are constructed through preprocessing. A two-layer graph attention network with residual connections is used to encode cross-molecular features. Then, a difficult negative sampling strategy is introduced to screen high-confidence negative samples, improving the ability to distinguish boundary samples. Simultaneously, a pairwise AUC loss function is used to optimize ranking performance, and three optimizers—Adam, PESG, and SGD—are combined for collaborative updates to achieve simultaneous improvement in local convergence and global ranking ability. Furthermore, the weights of positive samples are fixed outside the training loop. This invention significantly improves the prediction performance of T lymphocyte-antigen binding, effectively solving problems such as extreme sample imbalance, performance instability, and redundant training computation, providing a reliable and efficient computational tool for research on immune recognition mechanisms and precision immunotherapy.

The application discloses a CD19-targeting bifunctional bridging molecule and application thereof in improving CAR-T cell targeting and curative effect. In view of the bottleneck of solid tumor target deficiency and antigen heterogeneity, the bifunctional "bridging molecule" DBCO-CD19 is covalently anchored on metabolic marker tumor cells with azido groups (-N3) on the surface by metabolic sugar engineering and copper-free click chemistry, so that the tumor cell surface presents CD19 antigens. The strategy converts the heterogeneous tumor atlas into a single standard CD19 target, and breaks away from the dependence on natural antigen expression. With the aid of the bridging molecule, CD19 CAR-T cells can establish precise immune recognition with target cells, and induce the formation of stable immune synapses. Research proves that the strategy can drive CAR-T cells to efficiently remove various tumors, significantly enhance deep infiltration of three-dimensional tumor spheres, and exhibit significant and continuous tumor regression.

The present disclosure provides immunogenic compositions and methods for vaccination with a CelTOS immunogen. The immunogenic composition comprises Babesia, Theileria or Cytauxzoon CelTOS. The immunogenic composition may also comprise CelTOS with structural changes that affect immune recognition.